Full-Time
Associate Scientist II
Analytical Development, Raw Materials
Confirmed live in the last 24 hours
Vaxcyte
201-500 employees
Develops vaccines for bacterial infections
Compensation Overview
$105k - $114kAnnually
Mid, Senior
San Carlos, CA, USA
This position is a lab-based role and requires onsite presence.
- BS in Chemistry, Analytical Chemistry preferred, Organic / Biochemistry considered, with 2-6 years of relevant industry experience or MS with 1-4 years.
- Experience in chemical and biological assays such as colorimetric/ fluorometric microplate assays, HPLC, CE, UV-Vis, ELISA and LC-MS.
- Understanding of basic principles of analytical method development/ validation/ qualification concepts.
- Attention to detail and excellent skills in record keeping/documentation.
- Strong interpersonal skills and ability to communicate effectively both verbally and in written formats.
- This position is a lab-based role and requires onsite presence.
- Assist in analytical method development of new assays.
- Perform analytical testing, data analysis and present in team meetings.
- Maintain thorough and accurate records of laboratory work.
- Support daily lab operations, sample inventory and sample shipment.
- Author analytical documents including but not limited to test method, protocols, and reports.
Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while stimulating an immune response. Unlike traditional cell-based methods, their approach allows for the development of broad-spectrum vaccines. Vaxcyte's goal is to provide effective vaccines that can significantly reduce the impact of bacterial diseases on global health.
Company Stage
IPO
Total Funding
$273.3M
Headquarters
Foster City, California
Founded
2013
6 month growth
↑ 2%1 year growth
↑ 2%2 year growth
↑ 0%
Simplify's Take
What believers are saying
- FDA Breakthrough Therapy designation for VAX-24 may accelerate its market entry.
- Global pneumococcal vaccines market is projected to grow at a CAGR of 5.6% until 2030.
- Recent $1.5 billion public offering strengthens Vaxcyte's financial position for future developments.
What critics are saying
- Competition from mRNA technology developers like Moderna and BioNTech is intense.
- Potential regulatory delays could impact Vaxcyte's clinical trial timelines.
- Intellectual property disputes may arise over cell-free protein synthesis technology.
What makes Vaxcyte unique
- Vaxcyte uses a proprietary cell-free protein synthesis platform, XpressCF™, for vaccine development.
- Their lead product, VAX-24, targets 24 strains of Streptococcus pneumoniae bacteria.
- Vaxcyte focuses on broad-spectrum vaccines for bacterial infections, unlike traditional methods.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Company Equity
Stock Options
Remote Work Options